within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01E_SulfonamidesAndTrimethoprim.J01ED08_Sulfaphenazole;

model Sulfaphenazole
  extends Pharmacolibrary.Drugs.ATC.J.J01ED08;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J01ED08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Sulfaphenazole is a sulfonamide antibacterial agent used historically for the treatment of bacterial infections. It belongs to the class of sulfonamides, which act by inhibiting bacterial folic acid synthesis. Due to the development of more effective and safer antibiotics, sulfaphenazole is rarely used clinically today and is not approved for contemporary therapeutic use in most regions. It is of particular interest in pharmacology as a potent and selective inhibitor of cytochrome P450 2C9 (CYP2C9) for research purposes.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for a typical adult after a single oral dose, as reported in literature on healthy male volunteers.</p><h4>References</h4><ol><li><p>Odegaard, SA (1986). Pharmacokinetics of sulfaphenazole in sheep. <i>Acta veterinaria Scandinavica</i> 27(2) 243–249. DOI:<a href=&quot;https://doi.org/10.1186/BF03548168&quot;>10.1186/BF03548168</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3799400/&quot;>https://pubmed.ncbi.nlm.nih.gov/3799400</a></p></li><li><p>Van Duijkeren, E, et al., &amp; Van Miert, AS (1994). Trimethoprim/sulfonamide combinations in the horse: a review. <i>Journal of veterinary pharmacology and therapeutics</i> 17(1) 64–73. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2885.1994.tb00524.x&quot;>10.1111/j.1365-2885.1994.tb00524.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8196097/&quot;>https://pubmed.ncbi.nlm.nih.gov/8196097</a></p></li><li><p>Vree, TB, et al., &amp; Hekster, YA (1990). High pressure liquid chromatographic analysis and preliminary pharmacokinetics of sulfaphenazole and its N2-glucuronide and N4-acetyl metabolites in plasma and urine of man. <i>Pharmaceutisch weekblad. Scientific edition</i> 12(6) 243–246. DOI:<a href=&quot;https://doi.org/10.1007/BF01967825&quot;>10.1007/BF01967825</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2091020/&quot;>https://pubmed.ncbi.nlm.nih.gov/2091020</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Sulfaphenazole;
